Related Experiment Video
Updated: Sep 13, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Mitophagy: A Potential Therapeutic Target for Tuberculosis Immunotherapy.
Siyu Gao1, Zeliang Yang1, Jiajia Yu2
1Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People's Republic of China.
Mitophagy, the process of clearing damaged mitochondria, is crucial for fighting Mycobacterium tuberculosis infection. Activating mitophagy offers a promising therapeutic strategy against tuberculosis.
Area of Science:
- Cellular Biology
- Immunology
- Microbiology
Background:
- Mitophagy is a key cellular process for maintaining mitochondrial quality and homeostasis.
- Mycobacterium tuberculosis infection critically impacts host cell fate and function through mitochondrial manipulation.
Purpose of the Study:
- To provide a comprehensive overview of the interaction between Mycobacterium tuberculosis and mitophagy.
- To identify signaling pathways and potential therapeutic targets for host-directed therapies against tuberculosis.
Main Methods:
- Literature review of studies on mitophagy and Mycobacterium tuberculosis.
- Analysis of molecular mechanisms underlying host-pathogen mitochondrial interactions.
- Identification of potential therapeutic targets within mitophagy pathways.
Main Results:
- Mycobacterium tuberculosis strategically manipulates host mitochondria, affecting apoptosis, metabolism, and reactive oxygen species.
- BNIP3/NIX-mediated mitophagy is highlighted as a potential therapeutic target.
- Activating mitophagy in infected cells shows promise for tuberculosis treatment.
Conclusions:
- Understanding Mycobacterium tuberculosis-mitophagy interplay is vital for developing effective host-directed therapies.
- Targeting mitophagy, particularly BNIP3/NIX pathways, presents a promising strategy to enhance tuberculosis treatment outcomes.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tumor Immunotherapy